LA JOLLA, Calif., Sept. 8, 2016 /PRNewswire/ -- StemGenex, a world leader offering access to autologous adipose-derived stem cell treatment, recently announced it has named Steven A. Brody, M.D., Ph.D. Chief Scientific Officer. Dr. Brody is an internationally recognized physician-scientist specializing in regenerative and restorative medicine, bioidentical hormone therapy, and genomic methods to enhance health.
"We are enthusiastic about collaborating with Dr. Brody because of his wide range of research and clinical administration of scientific advancements that will change the future of medicine as we know it," said Dr. Andre Lallande, Medical Director. "His lifelong commitment to developments in reproductive medicine and laboratory innovations make him an excellent choice for Chief Scientific Officer."
In this new role, Dr. Brody will research the scientific basis of clinical procedures and laboratory techniques, objectively analyze clinical outcomes and lead compliance and regulatory initiatives.
"Stem cell therapy is the future of medicine. It has the potential to both repair and regenerate damaged tissues and organs," said Dr. Brody. "Clinical research and growth is vital in providing the highest quality and most effective therapy for patients."
Among its science and research initiatives, StemGenex sponsors five clinical studies registered with the National Institutes of Health for Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis. These have been established to evaluate the quality of life changes in individuals following adipose-derived stem cell treatment. Each clinical study has been approved by an independent institutional review board to ensure proper oversight and protocols are being followed.
"We consider clinical research a core competency and a significant advantage compared with adult adipose stem cell therapy and treatment centers offering unregistered studies," said Dr. Lallande.
Prior to joining StemGenex, Dr. Brody was Medical Director of Lifespan Medical Institute in La Jolla. He previously held positions of Director of Reproductive Endocrinology at Alvarado Hospital in San Diego and served in the military as Lieutenant Commander (surgeon) in the U.S. Public Health Service.
Dr. Brody received his medical degree from Washington U. School of Medicine and has trained at Yale-New Haven Hospital, the National Institutes of Health, Stanford University School of Medicine and Baylor College of Medicine.
A prolific researcher, Dr. Brody has authored a number of influential articles and has written two medical textbooks. He partnered with the 2010 Nobel Prize recipient in Medicine, Dr. Robert G. Edwards, to co-author the textbook, "Principals and Practice of Assisted Human Reproduction."
In recognition of his work, he was chosen San Diego's "Doctor of the Year" by the San Diego Medical Journal and Metropolitan Magazine.
StemGenex is committed to helping people with unmet clinical needs achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides access to stem cell therapy options to help individuals suffering with inflammatory and degenerative illnesses. Board Certified Physicians administer safe and effective adult adipose-derived stem cell therapy, a minimally invasive procedure using an individual's own stem cells to treat diseases including Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stemgenex-announces-steven-a-brody-md-phd-chief-scientific-officer-300324565.html